Subscribe

Yung Zip Chemical Ind. Co., Ltd. (4102.TWO)

TWD20.40 +0.15 (+0.74%)
TW TWO Healthcare Drug Manufacturers - General
Address 59, 61 You Shih Road 43767
Taichung, TW
CEO Ching Hwang Lin
Website yungzip.com
IPO 2007-12-31
ISIN TW0004102009

Explore sections of this company profile

Description

Yung Zip Chemical Ind. Co., Ltd. is a global provider specializing in the manufacture of essential pharmaceutical components. The company supplies active pharmaceutical ingredients (APIs), their intermediate precursors, and various specialty chemicals to markets around the world. Their diverse product portfolio includes a wide array of therapeutic agents addressing conditions such as hypertension, iron overload, inflammation, pain, fever, fungal infections, schizophrenia, blood clotting issues, genital herpes outbreaks, and sleep disorders (hypnotics and sedatives). In addition to these core offerings, Yung Zip also provides pharmaceutical excipients, such as sodium starch glycolate, and offers bespoke research, development, and manufacturing services. The company, established in 1978, is headquartered in Taichung, Taiwan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
TWD20.40 +0.15 (+0.74%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
79.2K
Beta
-0.05
Float Shares
31.16M
Free Float %
73.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.59% -3.70% -7.40% -15.50% -14.21% -14.86% -31.72% -52.39% -25.55% -19.71% +71.57%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
20.40
DCF (Unlevered) 21.80 +6.9%
DCF (Levered) 28.88 +41.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.31
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    -18.8% Q1'26: -4.5% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - General: +18.2%
    -122.4% Q1'26: +183.0% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    -7.7% Q1'26: +17.6% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    -4.2% Q1'26: +2.7% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    -2.7% Q1'26: +1.7% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    -0.6% ★ Q1'26: +21.3% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    -7.94× Q1'26: 13.52× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.09) × ERP
WACC = 82% × Ke + 18% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 21.80 Current price: 20.40
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
416.84M
est: 455.00M (-8.4%)
463.21M
est: 437.00M (+6.0%)
477.60M
est: 459.00M (+4.1%)
567.33M
est: 437.00M (+29.8%)
559.15M
est: 459.00M (+21.8%)
583.70M
est: 455.00M (+28.3%)
474.22M
est: 455.00M (+4.2%)
437.00M
437.00M – 437.00M
-4.0% YoY
459.00M
459.00M – 459.00M
+5.0% YoY
EBITDA
60.12M
est: 76.74M (-21.7%)
68.07M
est: 73.70M (-7.6%)
49.84M
est: 77.41M (-35.6%)
117.16M
est: 73.70M (+59.0%)
106.58M
est: 77.41M (+37.7%)
113.72M
est: 59.56M (+90.9%)
-19.83M
est: 59.56M (-133.3%)
57.20M
57.20M – 57.20M
-4.0% YoY
60.08M
60.08M – 60.08M
+5.0% YoY
EBIT
21.93M
est: 44.61M (-50.8%)
29.41M
est: 42.84M (-31.4%)
7.22M
est: 45.00M (-84.0%)
48.71M
est: 42.84M (+13.7%)
71.07M
est: 45.00M (+57.9%)
81.24M
est: 34.86M (+133.1%)
-19.83M
est: 34.86M (-156.9%)
33.48M
33.48M – 33.48M
-4.0% YoY
35.16M
35.16M – 35.16M
+5.0% YoY
Net Income
31.32M
est: 42.09M (-25.6%)
30.74M
est: 41.24M (-25.4%)
6.00M
est: 36.98M (-83.8%)
69.99M
est: 41.24M (+69.7%)
62.51M
est: 36.98M (+69.0%)
64.61M
est: 41.82M (+54.5%)
-10.07M
est: 41.82M (-124.1%)
40.98M
40.98M – 40.98M
-2.0% YoY
36.75M
36.75M – 36.75M
-10.3% YoY
SGA
63.70M
est: 66.65M (-4.4%)
72.54M
est: 64.01M (+13.3%)
66.06M
est: 67.24M (-1.7%)
81.32M
est: 64.01M (+27.0%)
83.77M
est: 67.24M (+24.6%)
84.25M
est: 52.40M (+60.8%)
—
est: 52.40M (-100.0%)
50.33M
50.33M – 50.33M
-4.0% YoY
52.86M
52.86M – 52.86M
+5.0% YoY
EPS
0.74
est: 0.99 (-25.3%)
0.73
est: 0.97 (-24.7%)
0.14
est: 0.87 (-83.9%)
1.65
est: 0.97 (+70.1%)
1.48
est: 0.87 (+70.1%)
1.52
est: 0.99 (+53.5%)
-0.34
est: 0.99 (-134.3%)
0.97
0.97 – 0.97
-2.0% YoY
0.87
0.87 – 0.87
-10.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 5/5 1/5 1/5 2/5 1/5 3/5
2026-05-28 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-27 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-26 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-25 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-22 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-21 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-20 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-19 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-18 C+ 2/5 4/5 1/5 1/5 2/5 1/5 3/5
2026-05-15 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-05-07 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-05-06 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-05-05 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-05-04 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-04-30 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-04-29 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-04-28 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-04-27 C+ 2/5 4/5 1/5 1/5 2/5 1/5 4/5
2026-04-24 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-72.47M
OE per share TTM
-1.79
Owner's Yield
-8.34%
Maintenance CapEx ratio
205.64%
Maint CapEx / Avg PPE
74.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-104.9K
Shares Outstanding
42.37M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Ching Hwang Lin Chairman & President — —
Yufang Wang Accounting Supervisor — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General